Circulating natriuretic peptide concentrations in patients with end-stage renal disease: Role of brain natriuretic peptide as a biomarker for ventricular remodeling

Mayo Clinic Proceedings

Volumn 76, Issue 11, 2001, Pages 1111-1119

  Cataliotti, Alessandro ^a   Malatino, Lorenzo S ^b   Jougasaki, Michihisa ^a,f,g,h   Zoccali, Carmine ^d,e   Castellino, Pietro ^b   Giacone, Giuseppe ^b   Bellanuova, Ignazio ^b   Tripepi, Rocco ^d,e   Seminara, Giuseppe ^a   Parlongo, Saverio ^d,e   Stancanelli, Benedetta ^b   Bonanno, Grazia ^c   Fatuzzo, Pasquale ^c   Rapisarda, Francesco ^c   Belluardo, Paola ^b   Signorelli, Salvatore S ^b   Heublein, Denise M ^a   Lainchbury, John G ^a   Leskinen, Hanna K ^a   Bailey, Kent R ^a   Redfield, Margaret M ^a   Burnett, John C ^a   more..

^a MAYO CLINIC   (United States)

^b Istituto di Clinica Medica Luigi Condorelli   (United States)

^c Divisione Clinicizzata di Nefrologia Chirurgica   (United States)

^d UNIVERSITY OF CATANIA   (Italy)

^e CNR   (Italy)

^f NATIONAL HOSPITAL ORGANIZATION KAGOSHIMA MEDICAL CENTER   (Japan)

^g UNIVERSITY OF OTAGO   (New Zealand)

^h UNIVERSITY OF OULU   (Finland)

Author keywords

ANP = atrial natriuretic peptide; AUC = area under the curve; BNP = brain natriuretic peptide; CAD = coronary artery disease; CHF = congestive heart failure; CNP = C type natriuretic peptide; DNP = Dendroaspis natriuretic peptide; DNP LI = DNP like immunoreactivity; ESRD = end stage renal disease; IVST = intraventricular septum thickness; Kt V = fractional urea clearance rate; LVD = left ventricular systolic dysfunction; LVEF = left ventricular ejection fraction; LVH = left ventricular hypertrophy; LVMI = left ventricular mass index; MI = myocardial infarction; NP = natriuretic peptide; PWT = posterior wall thickness; ROC = receiver operating characteristic

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC PEPTIDE TYPE C;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; ECHOCARDIOGRAPHY; FEMALE; HEART DEATH; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE REMODELING; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS;

EID: 0034765282     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/76.11.1111     Document Type: Article

References (30)

1. Natriuretic peptides
2. Circulating N-terminal pro-atrial natriuretic peptide is an independent predictor of left ventricular hypertrophy in the general population: The Tromsø study
3. Atrial natriuretic peptide elevation in congestive heart failure in the human
4. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
5. Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease
6. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps)
7. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure
8. Renal actions of synthetic Dendroaspis natriuretic peptide
9. Causes of death: USRDS: United States Renal Data System
10. Outcome and risk factors for left ventricular disorders in chronic uraemia
11. Echocardiographic findings in long-term, long-hour hemodialysis patients
12. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
13. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure
14. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention
15. Impact of left ventricular hypertrophy on survival in end-stage renal disease
16. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements
17. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
18. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
19. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach
20. Plasma human brain natriuretic peptide in chronic renal failure
21. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure
22. Plasma level of atrial natriuretic peptide as an indicator of increased cardiac load in uremic patients
23. Differential regulation of brain and atrial natriuretic peptides in hemodialysis patients
24. C-type natriuretic peptide in chronic renal failure and its action in humans
25. Plasma concentration of brain natriuretic peptide as an indicator of cardiac ventricular function in patients on hemodialysis
26. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients
27. Differential modulating actions of the natriuretic peptides upon endothelial cell function
28. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study
29. Plasma brain natriuretic peptide-an independent predictor of cardiovascular mortality in acute heart failure